Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Hair loss is linked to cellular physiology and the IGF-1 to TGF-B1 ratio, not just androgen sensitivity. The theory lacks evidence, while finasteride and minoxidil are effective treatments.

RU58841 is discussed as a hair loss treatment, with concerns about its effectiveness diminishing after two years due to androgen receptor upregulation. The user is hesitant to start using it, fearing it may worsen their condition over time.

A 20-year-old female with PCOS is experiencing hair loss and excessive facial hair. She is using ketoconazole and caffeine shampoos, microneedling, and considering anti-androgens like finasteride, but is cautious about minoxidil due to facial hair concerns.

Exploring the idea of using facial hair properties for scalp regeneration in male pattern baldness, considering the potential of transferring androgen-resistant characteristics from facial hair to the scalp. Challenges include complexity, scalability, aesthetics, and safety, but the concept encourages innovative thinking beyond current treatments like Minoxidil, Finasteride, and hair transplants.

Microneedling with RU58841 may not be necessary since RU works topically by occupying receptors before DHT binds. RU58841 is a topical anti-androgen.

A 27-year-old male is experiencing a recurring pattern of hair loss after 5 months of using oral minoxidil and finasteride, despite initial success. He is considering using topical androgen receptor blockers like RU58841, pyrilutamide, or clascoterone to address potential androgen receptor hypersensitivity.

PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.

RU58841 worsened hair condition, causing thinning and unusual patterns. The user stopped using it two months ago but hasn't seen recovery, and there's speculation about androgen receptor upregulation.

A 30-year-old woman with androgenetic alopecia is considering bicalutamide to slow hair loss but is concerned about its impact on muscle growth due to its anti-androgen effects. Alternatives suggested include dutasteride, spironolactone, RU58841, and minoxidil, with concerns about bicalutamide's side effects.

A 15-year-old is experiencing hair loss and has tried rosemary and jojoba oils without success. They are advised to see a doctor for thyroid and androgen tests and consider using Minoxidil.

A 19-year-old is seeking advice on reversing hair loss without a transplant, currently using oral finasteride and topical minoxidil. A suggestion was made to switch to dutasteride and use a stronger minoxidil, with the addition of a topical anti-androgen after three months.

The conversation is about receiving a shipment of Koshine, also known as Kintor, which is an anti-androgen treatment for hair loss. The user is eager to try the KX-826 product and observe its effects and any side effects.

A 21-year-old is using Dualgen-5R (minoxidil and tretinoin) and weekly dermarolling to address hair loss, noticing some progress after three months. They plan to add an anti-androgen like RU58841 or Kx826 for better long-term results.

The user experienced minor hair regrowth after three months using chewable minoxidil and finasteride, but had to stop dutasteride due to severe side effects. They added topical minoxidil and microneedling to their routine and are considering topical anti-androgens for further improvement.

The conversation discusses a hair loss treatment regimen involving finasteride, dutasteride, spironolactone, bicalutamide, oral estradiol, microneedling, and minoxidil. The regimen aims to reduce androgenic alopecia by blocking DHT and androgens, with a caution about potential feminizing effects.

Users discuss whether Koshine reduces sebum and scalp itchiness. Some report reduced sebum and seborrheic dermatitis, while others debate the effectiveness of anti-androgens like RU58841 for hair loss.

Exploring hair loss treatments beyond DHT, including Minoxidil, pyruvate, Gt20029 targeting androgen receptors, and vasodilators. Other options like Kx826, adenosine signaling, growth factor topicals, and microneedling are also discussed.

A new hair loss treatment, Pyrilutamide, has been released and is claimed to be a strong anti-androgen, potentially effective when used with finasteride. However, there are mixed opinions on its effectiveness and safety, with some users skeptical and others purchasing it.

A user is experiencing continued hair loss despite using 0.5mg dutasteride and 2.5mg minoxidil, and is seeking advice on why the treatments aren't working and how to address potential androgen receptor sensitivity. Replies suggest getting tested and considering scalp micropigmentation (SMP).

The conversation is about the results of using hormone replacement therapy (HRT) with estrogen and finasteride for hair loss, and switching from finasteride to bicalutamide as an anti-androgen treatment. The user shared before and after photos to discuss the effectiveness of these treatments.

The conversation discusses whether finasteride's reduction of DHT and increase in scalp testosterone contribute to hair follicle miniaturization. Some participants argue testosterone does not cause miniaturization, while others suggest that even with reduced DHT, other androgens like testosterone may still contribute to hair loss.

A user experienced severe chest pains and shortness of breath after using RU58841 for hair loss and was advised by a doctor that blocking androgens can weaken the heart. They decided to continue with finasteride, minoxidil, and a hair transplant instead.

The conversation discusses whether creatine causes hair loss for those using finasteride or dutasteride, with some suggesting creatine might increase DHT or upregulate androgen receptors, potentially leading to hair loss. Others argue the evidence is not conclusive, citing limited studies and personal anecdotes, with some avoiding creatine as a precaution.

The conversation discusses doubts about the effectiveness of topical finasteride for hair loss, suggesting that DHT could be produced elsewhere in the body and affect the scalp. It proposes that androgen receptor antagonists like spironolactone and clascoterone might be more effective as they could prevent this potential bypass mechanism.

A transgender individual is starting spironolactone and estradiol for hormone replacement therapy (HRT) and is considering adding finasteride to help with hair loss. They are also planning to use minoxidil and microneedle, but are unsure if they need to use another anti-androgen or more aggressive treatments. A respondent advises against using pyri and suggests waiting to see if the HRT alone is sufficient before becoming dependent on minoxidil.

He Shou Wu (Fo Ti) extract was found to prolong the hair growth phase, inhibit 5-alpha-reductase (like finasteride), reduce androgen receptors, and increase growth factors, potentially outperforming minoxidil in recovering hair follicle size after DHT exposure. Two compounds, emodin and TSG, are identified as responsible for these effects and warrant further investigation.

Pyrilutamide is believed to be more effective than RU58841 and 1 mg finasteride in treating hair loss, with no systemic hormonal effects and the potential to block more than 31% of scalp DHT. It may also antagonize scalp testosterone due to its action as an androgen receptor antagonist.

User asks if dutasteride destroys hairlines. Some users share negative experiences, while others report improvement or no issues. Advice given: start with finasteride and consider anti-androgens if needed.

Hair loss treatments Cosmerna, RU, and Pyri discussed. Cosmerna inhibits androgen receptors, but not 100%, so RU/Pyri can be used synergistically.

Gym and creatine can cause hair loss by increasing testosterone and androgenic activity. DHT blockers may help some, while others need androgen suppression with topical AA like RU or Pyri.